


Proven patency. Measurable value.



Overall weighted average primary patency

GORE® PROPATEN® Vascular Graft



OVER
600,000
devices implanted



OVER
2,000
limbs studied



OVER
30
clinical publications

LASTING
THROMBORESISTANCE
PROVEN
TECHNOLOGY
CBAS HEPARIN SURFACE[†]

Walk through the data –
Explore the interactive data summary at
propatenperformance.com

* Overall weighted average primary patency is based on data from 12 peer-reviewed publications meeting pre-determined inclusion criteria. Visit propatenperformance.com to see inclusion criteria, explore the data, see publications, and request reprints.

† CBAS Heparin Surface. W. L. Gore & Associates Web site. <https://www.goremedical.com/cbas/references>. Accessed July 30, 2018.

1. Dorigo W, Raffaele P, Piffaretti G. Results from an Italian multicentric registry comparing heparin-bonded ePTFE graft and autologous saphenous vein in below-knee femoro-popliteal bypasses. *Journal of Cardiovascular Surgery* 2012;53(2):187-193.

2. Monaca V, Battaglia G, Turiano SA, Tringale R, Catalfamo S. Sub popliteal revascularization. Criteria analysis for use of E-PT.F.E. (Propaten[®]) as first choice conduit. *Italian Journal of Vascular & Endovascular Surgery*. 2013;20(3):165-169.

W. L. Gore & Associates, Inc. | Flagstaff, AZ 86004 | goremedical.com

Products listed may not be available in all markets.

CBAS is a trademark of Camedia AB, a wholly owned subsidiary of W. L. Gore & Associates, Inc.

GORE, PROPATEN, and designs are trademarks of W. L. Gore & Associates.

© 2018, 2020 W. L. Gore & Associates GmbH AX1267-EN2 JULY 2020

